Business Standard

Covid-19 pandemic: Serum Institute seeks indemnity for jab again

In talks with RDIF to manufacture Sputnik V in India

Covishield
Premium

SII is selling the AstraZeneca vaccine named Covishield in India. It is also manufacturing the Novavax Covid-19 vaccine and would bring the same to the Indian market (Photo: PTI)

Sohini Das Mumbai
Pune-based vaccine maker Serum Institute of India (SII) has sought indemnity from the government of India from any claims linked to the use of their Covid-19 vaccines, according to sources. Meanwhile, the company is also in discussions with the Russian Direct Investment Fund (RDIF) to manufacture Sputnik V vaccine in India.
 
SII sources said the company was hoping that if legal protection or indemnity is given to foreign vaccine makers, the same would be applicable for all. SII had sought indemnity for Covishield, the AstraZeneca vaccine before it launched the same in India.
 
SII Chief Executive Adar Poonawalla

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in